Coral Olazagasti, Assistant professor at the Sylvester Cancer Center at University of Miami, shared a post on X:
“Exciting progress in treating recurrent metastatic nasopharyngeal cancer!
The first-ever clinical trial of ADCs shows a 40% overall response rate, offering hope for patients with limited options.
A step forward!”
Olazagasti highlighted encouraging results from the first antibody-drug conjugate (ADC) trial in recurrent metastatic nasopharyngeal cancer, reporting a 40% overall response rate.
More posts featuring Coral Olazagasti.
